APA (7th ed.) Citation

Z, G., Y, J., N, X., W, Z., H, C., Y, W., . . . Y, D. (2026). Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety. CNS neuroscience & therapeutics, 32(6), e70921. https://doi.org/10.1002/cns.70921

Chicago Style (17th ed.) Citation

Z, Geng, et al. "Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety." CNS Neuroscience & Therapeutics 32, no. 6 (2026): e70921. https://doi.org/10.1002/cns.70921.

MLA (9th ed.) Citation

Z, Geng, et al. "Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety." CNS Neuroscience & Therapeutics, vol. 32, no. 6, 2026, p. e70921, https://doi.org/10.1002/cns.70921.